BMS-986408 + rabeprazole

BMS-986408 + rabeprazole is an investigational combination of a novel small molecule inhibitor, BMS-986408, and the proton pump inhibitor rabeprazole. BMS-986408 is a first-in-class, oral, dual inhibitor of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), which are negative regulators of T-cell receptor signaling. Inhibition of these enzymes potentiates T-cell activity and is designed to enhance anti-tumor immune responses. The combination with rabeprazole is being studied to evaluate the impact of altered gastric pH on BMS-986408’s absorption or pharmacokinetics, as is standard in early clinical drug development when oral small molecules may be affected by acid-modifying drugs[2][3][4][7]. The combination is currently in Phase 1/2 clinical investigation for advanced solid tumors[1][3][7].